Below $1 billion • 25%

$1 billion to $1.5 billion • 25%

$1.5 billion to $2 billion • 25%

Above $2 billion • 25%

Below $20 • 25%

$20 to $40 • 25%

$40 to $60 • 25%

Above $60 • 25%

Profitable • 25%

Break-even • 25%

Loss-making but stable • 25%

Facing financial distress • 25%

Above $50 • 25%

$30 to $50 • 25%

$10 to $30 • 25%

Below $10 • 25%

Revenue increases by 10% or more • 25%

Revenue stays within 10% of current levels • 25%

Revenue decreases by 10% or more • 25%

Cassava Sciences reports a loss • 25%

Stock price above $50 • 25%

Stock price between $20 and $50 • 25%

Stock price between $5 and $20 • 25%

Stock price below $5 • 25%

Above $200 million • 25%

Between $100 million and $200 million • 25%

Between $50 million and $100 million • 25%

Below $50 million • 25%

Outperforms • 33%

Performs similarly • 34%

Underperforms • 33%

Yes • 50%

No • 50%

Yes • 50%

No • 50%

New Alzheimer's drug candidate announced • 25%

Focus shifts to different therapeutic area • 25%

Company gets acquired • 25%

Continues current operations without major changes • 25%

Yes • 50%

No • 50%